secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001437749-23-014570
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics CEO resigns; Q1 net loss widens to $11.8M, revenue $2.9M
---------------------------------------------------------------------------

- CEO Richard W. Pascoe resigns effective June 1, 2023; Chief Development Officer Christal Mickle appointed interim CEO.
- Q1 net loss of $11.8M ($0.34 per share) vs $1.9M loss a year ago; revenue fell to $2.9M from $4.0M.
- Cash and investments $95.3M; expects operating runway into 2026, funding arimoclomol NDA resubmission and KP1077 program.
- Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023; KP1077 Phase 2 IH interim data expected Q3 2023.
- Share repurchases of 665,739 shares for ~$3.4M during Q1; $39.1M remaining under program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/kmph20230112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-014570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer